Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Controlled Trial to Assess the Immunogenicity and Safety of Full Versus Fractional Dose of Pfizer/BioNTech, AstraZeneca, and Sinovac COVID-19 Vaccines Given as a Booster Dose at Least 6 Months After Primary Vaccination Series or PCR-confirmed Infection With SARS-CoV-2 in Healthy Adults

NCT05343871 is registered in ClinicalTrials.gov with Albert B. Sabin Vaccine Institute as lead sponsor.

NCT NCT05343871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05343871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Controlled Trial to Assess the Immunogenicity and Safety of Full Versus Fractional Dose of Pfizer/BioNTech, AstraZeneca, and Sinovac COVID-19 Vaccines Given as a Booster Dose at Least 6 Months After Primary Vaccination Series or PCR-confirmed Infection With SARS-CoV-2 in Healthy Adults
Lead sponsor
Albert B. Sabin Vaccine Institute
Phase
Phase 4
Overall status
Completed
Start date
July 5, 2022
Completion date
January 11, 2024
Enrollment
2,354 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19